title: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
abstract: BACKGROUND
  Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is destructive, causes complications, and does not prevent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye. Case series in which patients were treated with vascular endothelial growth factor inhibitors suggest that these agents may be useful in treating retinopathy of prematurity.
  
  
  METHODS
  We conducted a prospective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab monotherapy for zone I or zone II posterior stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity. Infants were randomly assigned to receive intravitreal bevacizumab (0.625 mg in 0.025 ml of solution) or conventional laser therapy, bilaterally. The primary ocular outcome was recurrence of retinopathy of prematurity in one or both eyes requiring retreatment before 54 weeks' postmenstrual age.
  
  
  RESULTS
  We enrolled 150 infants (total sample of 300 eyes); 143 infants survived to 54 weeks' postmenstrual age, and the 7 infants who died were not included in the primary-outcome analyses. Retinopathy of prematurity recurred in 4 infants in the bevacizumab group (6 of 140 eyes [4%]) and 19 infants in the laser-therapy group (32 of 146 eyes [22%], P=0.002). A significant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II disease (P=0.27).
  
  
  CONCLUSIONS
  Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina. This trial was too small to assess safety. (Funded by Research to Prevent Blindness and others; ClinicalTrials.gov number, NCT00622726.).
authors.affiliation: Department of Ophthalmology and Visual Science, University of Texas Health Science Center at Houston-Medical School, Houston, USA. helen.a.mintz-hittner@uth.tmc.edu
authors.forename: Helen A
authors.initials: HA
authors.lastname: Mintz-Hittner
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Kennedy
authors.forename: Alice Z
authors.initials: AZ
authors.lastname: Chuang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D053685:Laser Therapy / Q000009:adverse effects; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012171:Retinal Vessels; D012178:Retinopathy of Prematurity / Q000145:classification / Q000188:drug therapy* / Q000628:therapy; D012720:Severity of Illness Index
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab